All Releases
 |
Dynavax Reports First Quarter 2013 Financial Results
May 6, 2013
|
13.2 KB |
|
| |
BERKELEY, CA -- (Marketwired) -- 05/06/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2013. The Company had $105.4 million in cash, cash equivalents and marketable securities as of March 31, 2013. This compared to $125.1 million at December 31, 2012.
For t...
|
|
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors
Apr 30, 2013
|
11.3 KB |
|
| |
BERKELEY, CA -- (Marketwired) -- 04/30/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company's board of directors has appointed Eddie Gray chief executive officer and a member of Dynavax's board, effective May 1, 2013. Mr. Gray will succeed Dino Dina, M.D., Chief Executive Officer. Dr. Dina will remain a consulta...
|
|
Dynavax Appoints David Novack as Senior Vice President, Operations and Quality
Mar 21, 2013
|
8.4 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 03/21/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Novack to the position of Senior Vice President, Operations and Quality, effective March 25, 2013. Mr. Novack brings nearly 25 years of industry experience in manufacturing and supply chain operations, implementin...
|
|
Dynavax Reports Fourth Quarter and Year End 2012 Financial Results
Mar 1, 2013
|
13.3 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 03/01/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2012. The Company had $125.1 million in cash, cash equivalents and marketable securities as of December 31, 2012, following the fourth quarter repayment of a $15 million ...
|
|
Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference
Feb 26, 2013
|
7.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 02/26/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the Cowen and Company 33rd Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 8:40 a.m. Eastern Time (5:40 a.m. Pacific Time).
Dino Dina, M.D., Chief Executive Officer of Dynavax, wi...
|
|
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application
Feb 25, 2013
|
11.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 02/25/13 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine.
In th...
|
|
Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference
Dec 17, 2012
|
7.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 12/17/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).
Dino Dina, M.D., Chief Executive Officer of Dynavax, ...
|
|
Dynavax Announces FDA Advisory Committee Meeting Outcome for HEPLISAV(TM)
Nov 15, 2012
|
8.6 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 11/15/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (Committee) voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity. Additionally, the Committee voted eight to...
|
|
Dynavax Reports Third Quarter 2012 Financial Results
Nov 1, 2012
|
13.8 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 11/01/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2012. The Company had $148.3 million in cash, cash equivalents and marketable securities as of September 30, 2012.
Total revenues for the quarter ended September 30...
|
|
Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma
Oct 31, 2012
|
9.9 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 10/31/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under the terms of a collaboration announced in 2006, and Dyna...
|
|
Dynavax Announces FDA Advisory Committee to Review HEPLISAV(TM)
Aug 28, 2012
|
9.8 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 08/28/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that its Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to discuss HEPLISAV at its meeting on November 14-15, 2012. Dynavax's Bio...
|
|
Dynavax Marketing Authorization Application for HEPLISAV(TM) Accepted for Review by European Medicines Agency
Aug 22, 2012
|
9.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 08/22/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in...
|
|
Dynavax Appoints Christine Larson as Chief Financial Officer
Aug 13, 2012
|
8.1 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 08/13/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of Christine Larson to the position of Vice President and Chief Financial Officer, a newly created position. Ms. Larson brings nearly 25 years of experience as a financial professional to the role, including a background i...
|
|
Dynavax Reports Second Quarter 2012 Financial Results
Aug 1, 2012
|
11.6 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 08/01/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2012. The Company had $160.2 million in cash, cash equivalents and marketable securities as of June 30, 2012 as compared to $114.0 million at December 31, 2011. Total cash for the sec...
|
|
Dynavax Submits HEPLISAV(TM) for EU Marketing Authorization
Jul 24, 2012
|
8.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 07/24/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 y...
|
|
Dynavax Appoints David Happel Vice President, Global Sales and Marketing
Jul 10, 2012
|
10.4 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 07/10/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Happel to the position of Vice President of Global Sales and Marketing. Mr. Happel has more than 25 years of experience in the biotech and pharmaceutical industry, including senior level leadership roles in globa...
|
|
Dynavax to Present at the 7th Annual JMP Securities Healthcare Conference
Jul 9, 2012
|
7.1 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 07/09/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the 7th Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, at 10:00 a.m. EDT (7:00 a.m. PDT).
Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will ...
|
|
Dynavax Reports New CPT Code for Adult Two Dose Hepatitis B Vaccination Schedule
Jul 2, 2012
|
9.5 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 07/02/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Panel has established a CPT code for an adult 2 dose hepatitis B vaccination schedule. HEPLISAV™ will be reported using the new code, differentiating ...
|
|
Dynavax Announces FDA Acceptance of HEPLISAV(TM) BLA
Jun 26, 2012
|
8.5 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 06/26/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Food and Drug Administration (FDA) has accepted for review the U.S. Biologics License Application (BLA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in ...
|
|
Dynavax to Present at the Jefferies 2012 Global Healthcare Conference
May 29, 2012
|
7.3 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 05/29/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday, June 5, at 9:30 a.m. EDT (6:30 a.m. PDT).
Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a corporate ov...
|
|
|
